Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 2/20 | 0.54 |
| ▸ | CCND1 | P24385 | 2/20 | 0.54 |
| ▸ | CCND3 | P30281 | 2/20 | 0.54 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.54 |
| ▸ | CDK2 | P24941 | 15/20 | 0.53 |
| ▸ | CDK1 | P06493 | 7/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4490411 | 0.88 | CDK2 (0.57) | CDK4CCND1CCND3CDK6CDK2 | |
| SCHEMBL4517014 | 0.84 | CDK2 (0.69) | CDK2CDK1KCNH2 | |
| SCHEMBL4504492 | 0.82 | CDK2 (0.54) | CDK4CCND1CCND3CDK6CDK2 | |
| SCHEMBL4515739 | 0.78 | CDK2 (0.61) | CDK4CCND1CCND3CDK6CDK2 | |
| SCHEMBL31000111 | 0.76 | CDK4 (0.40) | CDK4CCND1CCND3CDK6CDK2 | |
| SCHEMBL31000255 | 0.75 | CDK4 (0.41) | CDK4CCND1CCND3CDK6CDK2 | |
| SCHEMBL4494755 | 0.75 | CDK2 (0.52) | CDK2CDK1KCNH2 | |
| SCHEMBL23003022 | 0.74 | CDK2 (0.64) | CDK4CCND1CDK6CDK2 | |
| SCHEMBL23063745 | 0.74 | CDK2 (0.64) | CDK4CCND1CDK6CDK2 | |
| SCHEMBL23003024 | 0.74 | CDK2 (0.64) | CDK4CCND1CDK6CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| EP-2032559-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007138268-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | CCNI, MKI67, CDK2 | CDK4 9/4885CCND1 21/4885CCND3 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.